Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPR3 | P17342 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094842 | 1.00 | CTSL (0.39) | CTSLACEAAK1SCN9AALDH1A1 | |
| SCHEMBL17094835 | 0.92 | AAK1 (0.38) | CTSLAAK1SCN9AALDH1A1NPSR1 | |
| SCHEMBL17094833 | 0.92 | AAK1 (0.38) | CTSLAAK1SCN9AALDH1A1NPSR1 | |
| SCHEMBL17094791 | 0.91 | AAK1 (0.43) | CTSLACEAAK1SCN9A | |
| SCHEMBL17094790 | 0.91 | AAK1 (0.43) | CTSLACEAAK1SCN9A | |
| SCHEMBL19181306 | 0.86 | ACE (0.43) | ACESCN9A | |
| SCHEMBL19181283 | 0.86 | ACE (0.43) | ACESCN9A | |
| SCHEMBL19181285 | 0.86 | ACE (0.43) | ACESCN9A | |
| SCHEMBL17062865 | 0.83 | CMA1 (0.41) | CTSLACESCN9AALDH1A1 | |
| SCHEMBL17062864 | 0.83 | CMA1 (0.41) | CTSLACESCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | CTSL 3881/4885ACE 4661/4885AAK1 3726/4885 |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | CTSL 4631/4885ACE 3368/4885AAK1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.